Zobrazeno 1 - 10
of 655
pro vyhledávání: '"ALK inhibitors"'
Autor:
Magdalena Zaborowska-Szmit, Sebastian Szmit, Marta Olszyna-Serementa, Katarzyna Zajda, Anna Janowicz-Żebrowska, Piotr Jaśkiewicz, Dariusz M. Kowalski, Maciej Krzakowski
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background Venous thromboembolic events (VTE) are often diagnosed in ALK-positive lung cancer although it has not been demonstrated how their co-occurrence affects patients' survival. Methods The study included patients with ALK-positive lun
Externí odkaz:
https://doaj.org/article/a856c97950ee4695991a974a13a48d93
Autor:
Ya-Kun Zhang, Jian-Bo Tong, Mu-Xuan Luo, Xiao-Yu Xing, Yu-Lu Yang, Zhi-Peng Qing, Ze-Lei Chang, Yan-Rong Zeng
Publikováno v:
Arabian Journal of Chemistry, Vol 17, Iss 9, Pp 105863- (2024)
Tumor stands as one of the principal contributors to global mortality. As research into tumor treatments advances, tumor inhibitors emerge as pivotal milestones in tumor therapy. Among these inhibitors, Anaplastic Lymphoma Kinase (ALK), a receptor ty
Externí odkaz:
https://doaj.org/article/ffe822a2043445429fb1b8edb83507da
Autor:
Muthiah Vaikundaraja Indhuja, Sivasree Kesana, Nikita Mehra, Parathan Karunakaran, Arun Kumar Rajan, Venkatraman Radhakrishnan, Perumal Kalaiyarasi Jayachandran
Publikováno v:
South Asian Journal of Cancer, Vol 13, Iss 02, Pp 121-125 (2024)
Externí odkaz:
https://doaj.org/article/20f8ca09aa0a4cc29d696c0cefb09b6a
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Objectives To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). Methods The included RCTs were identified thro
Externí odkaz:
https://doaj.org/article/87ad64929f394e64a6f2cb23a919ccdf
Autor:
Michał Gil, Magdalena Knetki-Wróblewska, Przemysław Niziński, Maciej Strzemski, Paweł Krawczyk
Publikováno v:
Annals of Medicine, Vol 55, Iss 1, Pp 1018-1028 (2023)
AbstractMetastases to the central nervous system (CNS) in patients with non-small cell lung cancer constitute an extremely difficult clinical problem, and their occurrence is associated with a poor prognosis. Due to the existence of the blood-brain b
Externí odkaz:
https://doaj.org/article/d944926d500c4a3c80977ba12df8b70e
Autor:
Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria
Publikováno v:
Cancer Treatment and Research Communications, Vol 41, Iss , Pp 100842- (2024)
Background: In untreated ALK-positive non-small cell lung cancer no randomized controlled trials (RCTs) are available directly comparing next-generation ALK-inhibitors. We conducted a sensitivity analysis using the likelihood of being helped or harme
Externí odkaz:
https://doaj.org/article/027ba545a3d04abb89e195068dc14876
Autor:
Ken Kodama, Toru Momozane, Kaichi Shigetsu, Hiroshi Takehara, Takamasa Toyofuku, Kinji Nishiyama, Genju Koh, Kiyoaki Uryu
Publikováno v:
Clinical Case Reports, Vol 12, Iss 1, Pp n/a-n/a (2024)
Key Clinical Message Under the current progression of molecular targeting or immune therapy, early detection and radiation therapy of iliopsoas metastasis will not only improve performance status but also enable the continuation of effective systemic
Externí odkaz:
https://doaj.org/article/926b34ac5fd242d386e0230aa2cb324c
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 5, Pp 400-406 (2023)
Lung cancer is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for approximately 80%-85% of all pathological types. Approximately 30%-55% of NSCLC patients develop brain metastases. It has been rep
Externí odkaz:
https://doaj.org/article/8e0e3eba503d4a8186f70efa0b4919f6
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5072-5092 (2023)
ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK
Externí odkaz:
https://doaj.org/article/237f3ac30475444a97d7a0d94817d83b
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 4, Pp 319-324 (2023)
Lung cancer is the most common in incidence and mortality worldwide. With the development of next generation sequencing (NGS) detection technology, more and more patients with rare anaplastic lymphoma kinase (ALK) fusion mutations were detected. A ca
Externí odkaz:
https://doaj.org/article/80b3ff644ed8441b84debc16ed06ab30